My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 9 498 / DOI: 10.3332/ecancer.2015.498

Policy

PACE Continuous Innovation Indicators—a novel tool to measure progress in cancer treatments

Concerns about rising health care costs and the often incremental nature of improvements in health outcomes continue to fuel intense debates about ‘progress’ and ‘value’ in cancer research. In times of tightening fiscal constraints, it is increasingly important for patients and their representatives to define what constitutes ’value’ to them. It is clear that diverse stakeholders have different priorities. Harmonisation of values may be neither possible nor desirable. Stakeholders lack tools to visualise or otherwise express these differences and to track progress in cancer treatments based on variable sets of values.

The Patient Access to Cancer care Excellence (PACE) Continuous Innovation Indicators are novel, scientifically rigorous progress trackers that employ a three-step process to quantify progress in cancer treatments: 1) mine the literature to determine the strength of the evidence supporting each treatment; 2) allow users to weight the analysis according to their priorities and values; and 3) calculate Evidence Scores (E-Scores), a novel measure to track progress, based on the strength of the evidence weighted by the assigned value.

We herein introduce a novel, flexible value model, show how the values from the model can be used to weight the evidence from the scientific literature to obtain E-Scores, and illustrate how assigning different values to new treatments influences the E-Scores.

The Indicators allow users to learn how differing values lead to differing assessments of progress in cancer research and to check whether current incentives for innovation are aligned with their value model. By comparing E-Scores generated by this tool, users are able to visualise the relative pace of innovation across areas of cancer research and how stepwise innovation can contribute to substantial progress against cancer over time. Learning from experience and mapping current unmet needs will help to support a broad audience of stakeholders in their efforts to accelerate and maximise progress against cancer.

Keywords: cancer, innovation, value, indicators, progress

Loading Article Metrics ... Please wait

Author interviews

Gordon McVie

European Institute of Oncology, Milan, Italy and Founding Editor of ecancer.org

Related videos

Related articles

Conference Report: Highlights from the first ecancer–Liga Colombiana contra el Cancer conference, 17–18 November 2016, Bogota, Colombia

Abstract | Full Article | PDF | Spanish Published: 28 Mar 2017 / DOI: 10.3332/ecancer.2017.730

Conference Report: Highlights from the ecancer Future Horizons in Lung Cancer conference, 1–2 September 2016: Focusing on the future of treatment for NSCLC and SCLC

Abstract | Full Article | PDF Published: 23 Mar 2017 / DOI: 10.3332/ecancer.2017.729

Conference Report: Highlights from the 36th European Society of Surgical Oncology Congress (ESSO 36), 14–16 September 2016, Kracow, Poland: optimising European cancer surgery

Abstract | Full Article | PDF Published: 23 Mar 2017 / DOI: 10.3332/ecancer.2017.728

Short Communication: Clinical response in patients with ovarian cancer treated with metronomic chemotherapy

Abstract | Full Article | PDF Published: 28 Feb 2017 / DOI: 10.3332/ecancer.2017.723

Clinical Study: Perceived utility of an integrated psychological intervention for gynaecological cancer patients admitted for surgery: preliminary data

Abstract | Full Article | PDF Published: 23 Feb 2017 / DOI: 10.3332/ecancer.2017.722



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence